Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti ù 77,22 € (-1,96%). La mediana ù 86,41 € (+9,71%).

Acquista
  9
Mantieni
  2
Vendi
  1

Discussioni nella community


  • Solventum sharpens medtech strategy and plans spin-off of HIS division

    Solventum announced at the Wells Fargo healthcare conference that it will focus more on medical technology and spin off its Healthcare Information Services (HIS) unit, with options including sale, spin-off or partnership. The company raised its forecast for organic growth in 2026 to 2.5–3.0% but expects a near-term margin dilution of around 400 basis points from the HIS separation. MedSurg and dental (over 80% of the business) remain the main growth drivers; about 20 new products are planned by Q1 2028, with a target of 4–5% organic growth for 2028 (ex-HIS). » Altro su de.investing.com


  • Solventum reaches 52-week high at $88.21

    Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The health‑technology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fair‑value estimate signals as a slight overvaluation. » Altro su de.investing.com


  • UBS upgrade drives Solventum stock sharply higher

    UBS upgraded Solventum from “Neutral” to “Buy” and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » Altro su de.investing.com


  • Trian demands cost cuts, divestments and buybacks at Solventum after spin-off

    Trian Fund Management has disclosed just under a 5% stake in Solventum and, in an open letter, demanded three value-boosting measures: reduce overhead to 3M-levels, sell non-core divisions including Health Information Systems, and prioritize share buybacks. Trian criticizes that the market capitalization of around $12 billion is far below the $25 billion expected at the spin-off and sees about $13 billion of shareholder value destroyed. The investor also condemns high executive compensation since the spin-off without corresponding returns for shareholders and says it will communicate with other large shareholders and may adjust its position. » Altro su de.investing.com


  • Trian demands cost cuts, sale of non-core businesses and share buybacks at Solventum

    Trian Fund Management has disclosed an almost 5% stake in Solventum and, in an open letter, is calling for operational changes including reducing overhead to 3M levels, selling non-core divisions such as Health Information Systems, and prioritizing share buybacks. Trian criticizes Solventum for not delivering returns to shareholders since the spin-off and sees a dilution of company value compared with earlier analyst estimates. Solventum is trading near its 52-week low but remains profitable with earnings of $8.88 per share and a P/E ratio of 7.78. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Solventum ha registrato ricavi pari a 1,72 Mld € e un utile netto di -10,59 Mln €
(EUR) settembre 2026
YoY
Ricavi 1,72 Mld 3,66%
Utile lordo 937,59 Mln 6,52%
Utile netto -10,59 Mln 100,98%
EBITDA 50,32 Mln 96,57%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
13,77 Mld €
Numero di azioni
169,96 Mln
Massimo/minimo a 52 settimane
85,65 € - 56,74 €
Dividendi No
Beta
0,75
Rapporto P/E
100,09
Rapporto PEG
-1,11
Rapporto P/B
3,17
Rapporto P/S
1,85

Profilo aziendale

Solventum Corporation, un'azienda sanitaria, si occupa dello sviluppo, della produzione e della commercializzazione di un portafoglio di soluzioni per rispondere alle esigenze critiche di clienti e pazienti. Opera attraverso quattro segmenti: Medsurg, Dental Solutions, Health Information Systems e Purification and Filtration. Il segmento Medsurg fornisce soluzioni tra cui la cura avanzata delle ferite, la gestione dei siti I.V., la garanzia di sterilizzazione, la gestione della temperatura, forniture chirurgiche, stetoscopi ed elettrodi medicali. Il segmento Dental Solutions offre una suite completa di prodotti per odontoiatria e ortodonzia, tra cui bracket, allineatori, cementi restaurativi e agenti adesivi. Health Information Systems fornisce soluzioni software, tra cui sistemi assistiti da computer, documentazione medica, fatturazione diretta e automazione della codifica, metodologie di classificazione, piattaforme di riconoscimento vocale e di visualizzazione dei dati. Il segmento Purification and Filtration fornisce tecnologie di purificazione e filtrazione, tra cui filtri, purificatori, cartucce e membrane. La societĂ  Ăš stata costituita nel 2023 ed ha sede a Saint Paul, Minnesota.

Nome
Solventum
CEO
Bryan C. Hanson
Sede centrale Eagan, mn
Stati Uniti
Sito web
Settore
SanitĂ 
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
21/07/2014
Dipendenti 20.584

Simboli di borsa

Borsa Simbolo
NYSE
SOLV
Frankfurt
KB7.F
DĂŒsseldorf
KB7.DU
MĂŒnchen
KB7.MU
đŸȘ

Parqet  usa i cookie. Scopri di piĂč